Sentry Page Protection

D012

Submission To Be Reviewed

Title: La terapia adiuvante del cancro del colon nel paziente anziano

Journal Section

Abstract:

Incidence of colorectal cancer increases with advancing age and median age at diagnosis is 72 years. The benefit of adjuvant chemotherapy, with fluorouracil or capecitabine with or without oxaliplatin, has been established in many clinical trials. The impact of adjuvant chemotherapy on survival in older adults is not well defined, given that only a small percentage (< 10 %) of elderly patients (> 70 years) is included in these studies. Data from pooled-analysis support disease-free survival and overall survival benefit after fuorouracil-based adjuvant therapy in stage III elderly and fit patients. Instead, there is disagreement regarding benefit of adding oxalplatin in elderly patients. Disease-free survival benefit has been identified in some elderly patients,  however it is still not clear how to define this subset of patients.

The safety profile of doublet chemotherapy is similar when comparing age < 70 and >= 70 sub-groups.

Potential benefit from adjuvant chemotherapy in older adults must be weighTed against the risks attributable to increased toxicity, reduced organ function and limited social support. Comorbidities, as competing causes of death, play an essential role in determinig the survival of elderly patients and can diminish or negate the benefit of adjuvant chemotherapy.

Comprehensive geriatric assessment is recommended to define the presence or absence of frailty

 

Key words: 

elderly, colon cancer, adjuvant chemotherapy, comorbidities, geriatric assessment


Review Schedule

Editor's request 12-04-2018

Your Response 

Review Submitted 

Review Due 


REVIEW FORM RESPONSE

1) Does this paper present new ideas or results that have not been previously published? 2) Is the research presented in the article new or build upon existing research? 3) Does the article point out differences from related research?
OPTIONS
Does the article make a considerable contribution to the oncology field?
OPTIONS
1) Does the title clearly express the content of the article? Is 2) Is the abstract sufficiently informative and provides a good perspective on the final message of the aricle?
OPTIONS
1) Are the methods used clearly explained? 2) Are they a recognized approach? 3) Are the data and statistics used reliable?
OPTIONS
1) Are they clearly presented? 2) Do they avoid misinterpretation? 3) Do they sufficiently avoid assumptions and speculations?
OPTIONS
1) Do they reflect the latest research in the area? 2) Are they correctly indicated in article? 3) Are they correctly formatted according to the author guidelines?
OPTIONS
1) Are the tables correctly name and numbered? 2) Are the data presented in the table correctly interpreted in the article?
OPTIONS
1) Are the figures correctly named and numbered? 2) Do they properly illustrate what is discussed in the article? 3) Are they correctly interpreted in the article?
OPTIONS
1) Is the article clearly written?
OPTIONS
1) Does the article fit the guidelines for the section as outlined in the instructions to authors?
OPTIONS
Please rate the article in priority for publication based on the interest to our readership and contribution to the oncology field. (5) Being of hieghest priority and (1) being the lowest.
OPTIONS